Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthequity (HQY) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Healthequity (HQY) over the last 13 years, with Q4 2025 value amounting to -$122.4 million.

  • Healthequity's Cash from Financing Activities fell 4851.18% to -$122.4 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$375.6 million, marking a year-over-year decrease of 35023.32%. This contributed to the annual value of $57.6 million for FY2025, which is 22238.14% up from last year.
  • As of Q4 2025, Healthequity's Cash from Financing Activities stood at -$122.4 million, which was down 4851.18% from -$108.1 million recorded in Q3 2025.
  • In the past 5 years, Healthequity's Cash from Financing Activities registered a high of $444.9 million during Q2 2021, and its lowest value of -$122.4 million during Q4 2025.
  • Over the past 5 years, Healthequity's median Cash from Financing Activities value was -$2.6 million (recorded in 2022), while the average stood at $5.2 million.
  • Per our database at Business Quant, Healthequity's Cash from Financing Activities tumbled by 811200.0% in 2021 and then skyrocketed by 829568.45% in 2024.
  • Healthequity's Cash from Financing Activities (Quarter) stood at -$47.2 million in 2021, then surged by 97.68% to -$1.1 million in 2022, then surged by 285.21% to $2.0 million in 2023, then plummeted by 4163.86% to -$82.4 million in 2024, then plummeted by 48.51% to -$122.4 million in 2025.
  • Its last three reported values are -$122.4 million in Q4 2025, -$108.1 million for Q3 2025, and -$56.6 million during Q2 2025.